HCPLive Rheumatology reports that a recent study has identified new subtypes of rheumatoid arthritis (RA) by evaluating molecular patterns in patient joint biopsies, providing insights into the disease's underlying biology.

Laura Donlin, PhD, co-senior author and co-director of the Derfner Foundation Precision Medicine Laboratory at HSS discusses this discovery, which has the potential to transform RA treatment by allowing clinicians to personalize treatment based on a patient's specific subtype, potentially leading to more effective and faster treatment outcomes.

“Our work identifying new subtypes of RA may pave the way for personalized treatment approaches. This discovery has the potential to revolutionize the current landscape of RA treatment by enabling doctors to tailor therapies based on the specific subtype a patient exhibits. This personalized approach may lead to more effective and efficient outcomes, reducing the current reliance on trial and error in treatment strategies,” explained Dr. Donlin. 

Read the full article at hcplive.com.